Your post suggests your ignorance. Truth be told ONXX was just a stale, stagnant stock for a long period of time. The same can be said for VRTX. I know - O owned both of them. While this won't be sold for 150 - the eventual binary event in December and Reduce - It was eventually provide shareholders with a similar payday.
I'm sorry, but did you just compare paydays from a cancer treatment stock and a stock for a company that offers yet one more fish oil pill that only reduces triglycerides? There are many many ways to reduce triglycerides my friend. Vascepa is just one more option to reduce triglycerides. In addition, no cv health benefits have been proven to follow from reducing triglycerides anyway. So, epa capsules that are rx quality that you can buy anywhere from many different companies, or an FDA approved treatment for cancer?
Triglyceride numbers move all the time. Physicians don't believe pushing around triglyceride numbers help your health anyway. And if a day ever comes where somebody can tie together "pushing around" triglyceride numbers and actual reduction in cv events, everyone will have a multitude of options to push around their triglyceride numbers. Vascepa will sit on the shelf with all the other rx quality fish oil pill options we have. Using pure epa rx quality fish oil is not the only way to lower triglycerides. And Vascepa isn't the only pure epa rx quality fish oil available, let alone all of the rx quality fish oil that offer rx quality epa and dha of varying ratios. Humans need both epa and dha anyway and on top of that, physicians will prefer the bioavailability of all natural triglycerides vs. ethyl ester fish oils, so Vascepa is the last place for a big payday. The value of the company is much lower, so watch the share price continue to adjust downward.
You have missed good opportunities in other stocks while losing a bunch of money hanging on during the slow decline of AMRN. Wake up.
. No wonder you keep missing the boat. You don't have a clue about anything at all.